Evidence map›Paper›PMID 31209779›Full record

ArticleMolecular imaging and biology2020

[

Kirstin A Zettlitz, Wen-Ting K Tsai, Scott M Knowles, Felix B Salazar, Naoko Kobayashi, Robert E Reiter, Anna M Wu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  3. Review
  4. ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [European journal of nuclear medicine and molecular imaging · 2025
    Article
  5. Preclinical Imaging of Prostate Cancer.Seminars in nuclear medicine · 2023
    Review
  6. Review
  7. Evaluation of [Molecular imaging and biology · 2020
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kirstin A ZettlitzCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. kzettlitz@coh.org.ORCID 0000-0003-4870-6603
Wen-Ting K TsaiCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Scott M KnowlesCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Felix B SalazarCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Naoko KobayashiDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Robert E ReiterDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Anna M WuCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USCity Of Hope National Medical Center · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Multifunctional immunoPET tracers for pancreatic and prostate cancerR01CA174294 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E, WU, ANNA M · 2013 to 2020
$3.3M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA174294
6 · The paper itself

Abstract

purposeA great challenge in the diagnosis and treatment of prostate cancer is distinguishing between indolent or local disease and aggressive or metastatic disease. Antibody-based positron emission tomography (immuno-PET) as a cancer-specific imaging modality could improve diagnosis of primary disease, aid the detection of metastases to regional lymph nodes as well as to distant sites (e.g., bone), and monitor response to therapy. PROCEDURE: In search for a more physiologically relevant disease model, a human prostate stem cell antigen knock-in (hPSCA KI) mouse model was generated. The use of a syngeneic prostate cancer cell line transduced to express human PSCA (RM-9-hPSCA) enabled the evaluation of anti-PSCA immuno-PET in immunocompetent mice and in the context of normal tissue expression of PSCA. Two PSCA-specific humanized antibody fragments, A11 minibody and A2 cys-diabody, were radiolabeled with positron emitters iodine-124 and zirconium-89, respectively ([

resultsThe hPSCA KI mice express PSCA at low levels in the normal prostate, bladder and stomach, reproducing the expression pattern seen in humans. [

conclusionTracer biodistribution was not significantly impacted by normal tissue expression of PSCA. [

Indexed as

RadioisotopesZirconiumAnimalsAntigens, NeoplasmCell Line, TumorCrosses, GeneticGPI-Linked ProteinsHumansIodine RadioisotopesMaleMiceMice, Inbred C57BLNeoplasm MetastasisNeoplasm ProteinsPositron Emission Tomography Computed TomographyProstateAntigens, NeoplasmGPI-Linked ProteinsIodine-124Iodine RadioisotopesNeoplasm ProteinsPSCA protein, humanRadioisotopesZirconiumZirconium-89Antibody fragmentDiabodyImmuno-PETIodine-124MinibodyProstate cancerProstate stem cell antigen (PSCA)Zirconium-89

Identifiers

PMID31209779
PMCPMC6920577
OpenAlexW2950071500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.